Selvita S.A. provides drug discovery, drug development, and contract testing services in Poland. The company offers computer-aided drug design and artificial intelligence solutions, including structure-based drug design, virtual screening, and bioinformatics; medicinal and synthetic, analytical, and solid state chemistry, as well as process chemistry and scale up, and compound management and libraries; structural biology, fragment-based drug discovery, protein production, modification, and characterization; vitro assays and model, mechanistic and target-focused profiling, vitro safety platform, translational research and biomarkers, and specialized discovery platform; vivo models, non-GLP toxicology, histopathology, and tissue biobank; ADME and pharmacokinetic study, bioanalysis, DMPK strategy, and modeling; and proteomic, transcriptomic, spatial mass spectrometry imaging, and data analysis services. It also provides antibody discovery, developability, antibody characterization, antibody engineering, and other modalities. In addition, the company offers active substance, raw materials and drug products comprising scale-up and process chemistry, solid state characterization, CMC analytical support, analytical methods development and validation, nitrozoamines and other impurities, impurities identification, quality control and QP release, stability studies, formulation development, and clinical supply GMP manufacturing; extractables and leachables, and packaging and functionality; bioanalysis of small molecules; and regulatory affairs. Further, it provides method development and validation, physicochemical properties determination, five batch analysis, one batch analysis, impurities identification, certification, stability studies, process chemistry, and solid state characterization services. The company was formerly known as Selvita CRO S.A. and changed its name to Selvita S.A. in October 2019. Selvita S.A. was founded in 2007 and is headquartered in Kraków, Poland.
